Tag: transarterial chemoembolization

RETNET

First release RETNET data show no difference in progression-free survival between...

New data from a prospective, multicentre randomised controlled trial show similar hepatic progression-free survival (hPFS) using bland transarterial embolization (TAE) or transarterial chemoembolization (TACE)...

New analysis benchmarks survival rates in unresectable intrahepatic cholangiocarcinoma patients undergoing...

Updating on a previous meta-analysis, new data which pooled survival estimates of patients undergoing transarterial radioembolization (TARE) has shown the treatment to be a...

‘A new narrative’: TACE in the age of Y90 and immunotherapy

Hotly debated across the Society of Interventional Oncology (SIO; 25–29 January 2024, Long Beach, USA) annual conference programme, speakers took to the stage to...
TRIMODALITY

HKUMed discovers new trimodality therapy for locally advanced liver cancer

A phase II clinical study on a trimodality therapy (START-FIT), conducted by the Departments of Surgery and Clinical Oncology, School of Clinical Medicine, University...
TACE

Conventional transarterial chemoembolization more cost-effective than drug-eluting embolic TACE

Compared with doxorubicin-loaded drug-eluting embolic transarterial chemoembolization (DEE-TACE), conventional transarterial chemoembolization (cTACE) yielded a higher number of quality-adjusted life years (QALY) at a lower...

International survey reveals high variability in TACE technique

Transarterial chemoembolization (TACE) is a mainstay of locoregional treatment for hepatocellular carcinoma (HCC) in the intermediate stage. “The technique for this procedure, however, continues...